Sawinski Deirdre, Trofe-Clark Jennifer
Department of Medicine, Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA.
Clin Transpl. 2015;31:249-256.
BK virus (BKV) viremia is a common complication of kidney transplantation. In 2008, we enacted a screening protocol to detect BKV infection at our institution. The cumulative incidence of BKV viremia at our center is 24%, with most cases being detected in the first year post-transplant. We have previously identified the development of de novo donor specific antibody as a consequence of BKV infection treated with immunosuppression reduction; in this report, we confirm our prior findings and extend them to include an association of both Class I and Class II antibodies with BKV viremia. While with a median time of 4 years follow up there was no difference in patient or allograft survival on the basis of BKV viremia. Identification of treatment strategies for BKV that will prevent complications such as donor specific antibodies should be a research priority in this area.
BK病毒（BKV）血症是肾移植常见的并发症。2008年，我们制定了一项筛查方案，以在本机构检测BKV感染。我们中心BKV血症的累积发病率为24%，大多数病例在移植后的第一年被检测到。我们之前已经确定，降低免疫抑制治疗BKV感染会导致新生供体特异性抗体的产生；在本报告中，我们证实了之前的发现，并将其扩展至包括I类和II类抗体与BKV血症的关联。虽然中位随访时间为4年，但基于BKV血症，患者或移植肾的存活率并无差异。确定能预防供体特异性抗体等并发症的BKV治疗策略应是该领域的研究重点。
